Skip to main content
Top
Published in: Clinical Rheumatology 6/2007

01-06-2007 | Brief Report

Association of acute anterior uveitis with disease activity, functional ability and physical mobility in patients with ankylosing spondylitis: a cross-sectional study of Chinese patients in Taiwan

Authors: Chun-Hsiung Chen, Kuan-Chia Lin, Horng-An Chen, Hsien-Tzung Liao, Toong-Hua Liang, Hon-Pin Wang, Chung-Tei Chou

Published in: Clinical Rheumatology | Issue 6/2007

Login to get access

Abstract

Acute anterior uveitis (AAU) is the most frequently extra-articular manifestation of ankylosing spondylitis (AS). To investigate whether AAU has an association with disease activity, functional ability and physical mobility in AS patients, 146 Chinese AS patients in Taiwan were enrolled in a cross-sectional study. These patients fulfilled the 1984 modified New York criteria and visited the Outpatient Department of the Veterans General Hospital-Taipei from April 2004 to July 2005. Patients completed questionnaires assessing disease activity [Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)], functional ability [Bath Ankylosing Spondylitis Functional Index (BASFI)] and patient’s global assessment [Bath Ankylosing Spondylitis Patient Global Score (BAS-G)]. Meanwhile, physical examinations were performed, including Schober test, finger-to-floor, lateral spinal flexion, occiput-to-wall and chest expansion. The history of AAU was accepted only if diagnosed by an ophthalmologist. The prevalence of AAU in this Chinese AS cohort was 15.8% (23/146). Patients with AAU had a significantly higher BASDAI than those without [absolute differences=0.96, 95% confidence intervals (CI): 0.35∼1.88]. Additionally, patients with AAU had significantly increased BASFI than those without (absolute differences=1.46, 95% CI: 0.33∼2.59). Moreover, there was advanced limitation of physical motility in patients with AAU, including finger-to-floor, occiput-to-wall distances and Schober test, (95% CI: 3.89∼16.95 and p=0.046, respectively). Disease duration mildly correlated with BASFI (r=0.24, p=0.003) but not with BASDAI (p=0.838). There was no difference of disease duration between patients with and without AAU (p=0.343). These results suggested that the presence of AAU in AS patients may be associated with higher disease activity, poor functional ability and advanced physical impairment.
Literature
1.
go back to reference Brewerton DA, Hart FD, Nicholls A, et al (1973) Ankylosing spondylitis and HL-A 27. Lancet 1:904–907PubMedCrossRef Brewerton DA, Hart FD, Nicholls A, et al (1973) Ankylosing spondylitis and HL-A 27. Lancet 1:904–907PubMedCrossRef
2.
go back to reference Schlosstein L, Terasaki PI, Bluestone R, et al (1973) High association of an HL-A antigen, W27, with ankylosing spondylitis. N Engl J Med 288:704–706PubMedCrossRef Schlosstein L, Terasaki PI, Bluestone R, et al (1973) High association of an HL-A antigen, W27, with ankylosing spondylitis. N Engl J Med 288:704–706PubMedCrossRef
3.
go back to reference Gran JT, Skomsvoll JF (1997) The outcome of ankylosing spondylitis: a study of 100 patients. Br J Rheumatol 36:766–771PubMedCrossRef Gran JT, Skomsvoll JF (1997) The outcome of ankylosing spondylitis: a study of 100 patients. Br J Rheumatol 36:766–771PubMedCrossRef
4.
go back to reference Robertson LP, Davis MJ (2004) A longitudinal study of disease activity and functional status in a hospital cohort of patients with ankylosing spondylitis. Rheumatology (Oxford) 43:1565–1568CrossRef Robertson LP, Davis MJ (2004) A longitudinal study of disease activity and functional status in a hospital cohort of patients with ankylosing spondylitis. Rheumatology (Oxford) 43:1565–1568CrossRef
5.
go back to reference Ward MM, Weisman MH, Davis JC Jr, et al (2005) Risk factors for functional limitations in patients with long-standing ankylosing spondylitis. Arthritis Rheum 53:710–717PubMedCrossRef Ward MM, Weisman MH, Davis JC Jr, et al (2005) Risk factors for functional limitations in patients with long-standing ankylosing spondylitis. Arthritis Rheum 53:710–717PubMedCrossRef
6.
go back to reference van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27:361–368PubMedCrossRef van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27:361–368PubMedCrossRef
7.
go back to reference Garrett S, Jenkinson T, Kennedy LG, et al (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21:2286–2291PubMed Garrett S, Jenkinson T, Kennedy LG, et al (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21:2286–2291PubMed
8.
go back to reference Calin A, Garrett S, Whitelock H, et al (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21:2281–2285PubMed Calin A, Garrett S, Whitelock H, et al (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21:2281–2285PubMed
9.
go back to reference Jones SD, Steiner A, Garrett SL,et al (1996) The Bath Ankylosing Spondylitis Patient Global Score (BAS-G). Br J Rheumatol 35: 66–71PubMedCrossRef Jones SD, Steiner A, Garrett SL,et al (1996) The Bath Ankylosing Spondylitis Patient Global Score (BAS-G). Br J Rheumatol 35: 66–71PubMedCrossRef
10.
go back to reference Koh WH, Boey ML (1998) Ankylosing spondylitis in Singapore: a study of 150 patients and a local update. Ann Acad Med Singapore 27:3–6PubMed Koh WH, Boey ML (1998) Ankylosing spondylitis in Singapore: a study of 150 patients and a local update. Ann Acad Med Singapore 27:3–6PubMed
11.
go back to reference Jaakkola E, Herzberg I, Laiho K, et al (2006) Finnish HLA studies confirm the increased risk conferred by HLA-B27 homozygosity in ankylosing spondylitis. Ann Rheum Dis 65:775–780PubMedCrossRef Jaakkola E, Herzberg I, Laiho K, et al (2006) Finnish HLA studies confirm the increased risk conferred by HLA-B27 homozygosity in ankylosing spondylitis. Ann Rheum Dis 65:775–780PubMedCrossRef
12.
go back to reference Khan MA, Kushner I, Braun WE (1977) Comparison of clinical features in HLA-B27 positive and negative patients with ankylosing spondylitis. Arthritis Rheum 20:909–912PubMedCrossRef Khan MA, Kushner I, Braun WE (1977) Comparison of clinical features in HLA-B27 positive and negative patients with ankylosing spondylitis. Arthritis Rheum 20:909–912PubMedCrossRef
13.
go back to reference Braun J, Baraliakos X, Listing J, et al (2005) Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 52:2447–2451PubMedCrossRef Braun J, Baraliakos X, Listing J, et al (2005) Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 52:2447–2451PubMedCrossRef
Metadata
Title
Association of acute anterior uveitis with disease activity, functional ability and physical mobility in patients with ankylosing spondylitis: a cross-sectional study of Chinese patients in Taiwan
Authors
Chun-Hsiung Chen
Kuan-Chia Lin
Horng-An Chen
Hsien-Tzung Liao
Toong-Hua Liang
Hon-Pin Wang
Chung-Tei Chou
Publication date
01-06-2007
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 6/2007
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-006-0403-2

Other articles of this Issue 6/2007

Clinical Rheumatology 6/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine